The Expression of Interleukin-23 Receptor and Interleukin-17a in Patients with Inflammatory Bowel Disease and its Clinical Significance

Xi-xian CHENG,Rong WAN,Da-ru LU,Jie SHEN,Jing-ling SU
DOI: https://doi.org/10.13241/j.cnki.pmb.2011.21.022
2011-01-01
Abstract:Objective: To investigate the function and significance of interleukin-23 receptor(IL-23R) and interleukin-17a(IL-17A) in the pathogenesis of inflammatory bowel disease(IBD) by detecting the expression in the intestinal mucosal of patients with IBD.Methods: Intestinal or colonic mucosal biopsies of 32 patients with Crohn's disease(CD),29 patients with ulcerative colitis(UC) and 27 healthy controls were chosen.The expression of IL-23R and IL-17A was detected by real-time PCR and the situ expression of IL-23R and IL-17A in intestinal mucosa was analyzed with immunohistoehemistry.Results: Compared with that in healthy controls,the expression of IL-23R at mRNA level in inflamed mucosa of CD and UC patients increased significantly(P<0.05),and there was no statis-tic difference between CD and UC groups(P>0.05);The expression of IL-17A at mRNA level in inflamed mucosa of CD and UC patients increased significantly(P<0.05),and there was the statistic difference between CD and UC groups(P<0.05).The immunohisto-chemistry results indicated that more IL-23R and IL-17A positive cells were in the intestinal or colonic mucosa of UC and CD patient,and the expression of IL-23R and IL-17A in normal lamina mucosa was low.The expression of IL-23R and IL-17A protein in the intesti-nal or colonic mucosa of CD and UC patients increased significantly(P<0.05).Conclusion: The expression of IL-23R and IL-17A in the intestinal mucosa of IBD patients increased significantly,which suggested that abnormal IL-23R and IL-17A expression may had closely relation with the pathogenesis of IBD.IL-23R and IL-17A may be a new target for the IBD treatment.
What problem does this paper attempt to address?